{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:33:08Z","timestamp":1778826788076,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>Human chorionic gonadotropin (hCG) is dimeric glycoprotein produced by placenta in pregnancy and also in low levels by pituitary gland. The main clinical use for exogenous hCG\u2010administration is typically linked to infertility. The desired effect of hCG misuse in sport is due to the enhancement of testicular production of testosterone. Therefore, hCG is listed by the World Anti\u2010Doping Agency (WADA) as a prohibited substance in male athletes and according to the recently published WADA guideline urinary concentrations of hCG\u2009&gt;\u20095\u2009IU\/L may be an indicator of doping. In this study two independent immunoassays were used to implement the new WADA guideline. The assay for initial testing (Siemens Immulite 2000 XPi hCG assay) recognizes various hCG variants (e.g. hCG and \u03b2\u2010core fragment of hCG) whereas the confirmatory assay (PerkinElmer DELFIA Xpress hCG) is sensitive to intact and nicked hCG only. Both assays showed adequate sensitivity and were proven fit\u2010for\u2010purpose in routine doping control. Population\u2010based distribution of the assays was in good agreement with results of earlier studies and supported well the current threshold of 5\u2009IU\/L. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.1449","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T01:27:37Z","timestamp":1357781257000},"page":"614-618","source":"Crossref","is-referenced-by-count":15,"title":["Analysis of human chorionic gonadotropin (hCG): Application of routine immunological methods for initial testing and confirmation analysis in doping control"],"prefix":"10.1002","volume":"5","author":[{"given":"Tiia","family":"Kuuranne","sequence":"first","affiliation":[{"name":"Doping Control Laboratory, United Medix Laboratories  H\u00f6yl\u00e4\u00e4m\u00f6tie 14 00380 Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liisa","family":"Ahola","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory, United Medix Laboratories  H\u00f6yl\u00e4\u00e4m\u00f6tie 14 00380 Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Pussinen","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory, United Medix Laboratories  H\u00f6yl\u00e4\u00e4m\u00f6tie 14 00380 Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Leinonen","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory, United Medix Laboratories  H\u00f6yl\u00e4\u00e4m\u00f6tie 14 00380 Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dml029"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-123-1-572"},{"key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/clinchem\/43.7.1293","article-title":"Immunoprocedures for detecting human chorionic gonadotropin: Clinical aspects and doping control","volume":"43","author":"Stenman U.H.","year":"1997","journal-title":"Clin. Chem."},{"key":"e_1_2_5_5_1","first-page":"627","article-title":"The biological and clinical significance of nicks in human chorionic gonadotropin and its free beta\u2010subunit","volume":"64","author":"Cole L.A.","year":"1991","journal-title":"Yale J. Biol. Med."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/43.12.2233"},{"key":"e_1_2_5_7_1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/clinchem\/38.10.1981","article-title":"Concentrations of human choriogonadotropin, its \u03b2\u2010subunit, and the core fragment of the \u03b2\u2010subunit in serum and urine of nonpregnant women and men","volume":"38","author":"Alfthan H.","year":"1992","journal-title":"Clin. Chem."},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.102"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/17.3.625"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03516.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2569"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00536.2002"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021231"},{"key":"e_1_2_5_14_1","unstructured":"WADA.The World Anti\u2010Doping Code The 2012 prohibited list International Standard. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010Prohibited\u2010list\/2012\/WADA_Prohibited_List_2012_EN.pdf[12 June 2012]."},{"key":"e_1_2_5_15_1","unstructured":"WADA.Reporting & Management of Human Chorionic Gonadotropin Findings version 1.0 September 2011. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/Resources\/Guidelines\/WADA_Guidelines_Reporting_Management_hCG_findings_v1.0_EN.pdf[12 June 2012]."},{"key":"e_1_2_5_16_1","unstructured":"WADA.The World Antidoping Code ISL 7.0 \u2010 International Standard for Laboratories. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010IS\u2010Laboratories\/ISL\/WADA_Int_Standard_Laboratories_2012_EN.pdf. [12 June 2012]."},{"key":"e_1_2_5_17_1","unstructured":"WADA.2010 Adverse Analytical Findings and Atypical Findings Reported by Accredited Laboratories. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/Resources\/Statistics\/Laboratory_Statistics\/WADA_2010_Laboratory_Statistics_Report.pdf[12 June 2012]."},{"key":"e_1_2_5_18_1","unstructured":"WADA.World Anti\u2010Doping Program Guidelines hGH isoform differential immunoassays for anti\u2010doping analyses June 2010 Version 1.0. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/Resources\/Guidelines\/WADA_Guidelines_hGH%20Differential%20Immunoassays_EN_June10.pdf[12 June 2012]."},{"key":"e_1_2_5_19_1","first-page":"197","article-title":"Evaluation of two immunoassays for the measurement of human chorionic gonadotropin in urine for anti\u2010doping purposes","volume":"56","author":"Robinson N.","year":"2010","journal-title":"Clin. Lab."},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2007.06.015"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-971920"},{"key":"e_1_2_5_22_1","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/clinchem\/40.7.1306","article-title":"New decision limit and quality\u2010control material for detecting human chorionic gonadotropin misuse in sports","volume":"40","author":"Laider P.","year":"1994","journal-title":"Clin. Chem."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.08.006"},{"key":"e_1_2_5_24_1","first-page":"A36","article-title":"Sensitivity and linearity of hCG assays for nicked hCG: A comparative study [abstract]","volume":"44","author":"Ingen H.E.","year":"1998","journal-title":"Clin. Chem."},{"key":"e_1_2_5_25_1","unstructured":"WADA.Techical Document \u2013 TD2010MRPL September 2010. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010IS\u2010Laboratories\/Technical_Documents\/WADA_TD2010MRPLv1.0_Minimum%20Required%20Performance%20Levels_Sept%2001%202010_EN.pdf[12 June 2012]."},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.09.038"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.1449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.1449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:12:39Z","timestamp":1760382759000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.1449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1002\/dta.1449"],"URL":"https:\/\/doi.org\/10.1002\/dta.1449","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]}}}